

Dr. med. Christa Flechtenmacher
Institute of Pathology, Heidelberg



Institute of Pathology
Im Neuenheimer Feld 220
69120 Heidelberg

06221 56 39916 (phone)
06221 56 5251 (fax)
christa.flechtenmacher@med.uni-heidelberg.de

SCIENTIFIC VITA

- 1984-1991 Study of Medicine, scholarship Evangelisches Studienwerk e.V. Villigst
(German protestant church`s scholarship programme for gifted students)
- 1984-1986 University of Bochum/ Germany
- 1986-1988 University of Heidelberg/ Germany
- 1989 University of Minnesota and Yale University/ USA
- 1990 University of Zürich/ Switzerland
- 1990-1991 University of Heidelberg/ Germany
- 1991-1993 Institute of Pathology, Darmstadt
- 1993 MD-Thesis (Functional characterization of the role of PTH in the pathogenesis
of myocardial fibrosis and microarteriopathy in experimental uremia)
Institute of Pathology, University of Heidelberg
- 1994-1996 Sigel-Hospital, Langenbrücken, Internal medicine and gynecologic oncology
- since 1997 Institute of Pathology, University of Heidelberg
- 2001 Board Certification Pathology
- since 2001 Senior pathologist, Institute of Pathology, University of Heidelberg
Head of teaching program for dental school students
- since 2004 Quality manager, Institute of Pathology, University of Heidelberg

FIELDS OF INTEREST:

Diagnostics and research: tumours of the head and neck, molecular and morphological carcinogenesis (especially oral squamous cell carcinoma); liver and heart transplantation, tumours of the breast and female genital organs.
Teaching: new methods (e.g. implementation of an interviewing technique program with simulated relatives of passed away patients).
Quality management in medical institutions.

SELECTED PUBLICATIONS (SINCE 2000)

Freier K, Pungs S, Sticht C, Flechtenmacher C, Lichter P, Joos S, Hofele C
High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy.
Int J Cancer. 2007 Feb 15;120(4):942-6.

Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Lichter P, Joos S.
Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).
Oral Oncol. 2007 Jan;43(1):60-6. Epub 2006 Jun 27.

Berberat PO, Friess H, Schmied B, Kremer M, Gragert S, Flechtenmacher C, Schemmer P, Schmidt J, Kraus T, Uhl W, Meuer S, Buchler MW, Giese T.
Differentially expressed genes in postperfusion biopsies predict early graft dysfunction after liver transplantation.
Transplantation. 2006 Sep 15;82(5):699-704

Schemmer P, Liang R, Kincius M, Flechtenmacher C, Bunzendahl H, Gutt CN, Mehrabi A, Gebhard MM, Buchler MW, Kraus TW
Taurine improves graft survival after experimental liver transplantation.
Liver Transpl. 2005 Aug;11(8):950-9.

Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA.
Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies.
Virchows Arch. 2005 Apr;446(4):369-78. Epub 2005 Apr 2.

Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, Hergenbahn M, Weidauer H.
Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value.
Int J Cancer. 2004 Sep 10;111(4):530-8.

Szabo G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bahrle S, Seres L, Cziraki A, Gries A, Zsengeller Z, Vahl CF, Hagl S, Szabo C.
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporeal circulation.
Shock. 2004 May;21(5):426-32.

Engler S, Flechtenmacher C, Wiedemann KH, Gugler R, Stremmel W, Kallinowski B
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
J Viral Hepat. 2004 Jan;11(1):60-8.

Engler S, Elsing C, Flechtenmacher C, Theilmann L, Stremmel W, Stiehl A
Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders.
Gut. 2003 May;52(5):688-93.

Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, Lichter P, Hofele C.
Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.
Cancer Res. 2003 Mar 15;63(6):1179-82.

Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX.
Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control.
Oncogene. 2002 Feb 28;21(10):1510-7.